PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells

Cancer Research

Volumn 68, Issue 1, 2008, Pages 181-189

  Fazio, Grazia ^a,b   Palmi, Chiara ^a,b   Rolink, Antonius ^c   Biondi, Andrea ^a   Cazzaniga, Giovanni ^a,d  

^a SAN GERARDO HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF BASEL   (Switzerland)

^d Avancorpo Sett C Piano Terra   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CD19 ANTIBODY; CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; FLT3 LIGAND; HYBRID PROTEIN; PROTEIN BLNK; PROTEIN MB 1; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR PAX5; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; B CELL LINKER PROTEIN; CD135 ANTIGEN; CD19 ANTIGEN; CD79 ANTIGEN; INTERLEUKIN 7; ONCOPROTEIN; PAX5 PROTEIN, HUMAN; PAX5 TEL FUSION PROTEIN, HUMAN; PAX5-TEL FUSION PROTEIN, HUMAN; REPRESSOR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; ANIMAL; APOPTOSIS; B LYMPHOCYTE; CELL MOTION; CELL NUCLEUS; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; LYMPHATIC LEUKEMIA; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, CD19; ANTIGENS, CD79; APOPTOSIS; B-CELL-SPECIFIC ACTIVATOR PROTEIN; B-LYMPHOCYTES; CELL MOVEMENT; CELL NUCLEUS; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CHEMOKINE CXCL12; DOWN-REGULATION; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTERLEUKIN-7; LYMPHOCYTE ACTIVATION; MICE; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REPRESSOR PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 39149096620     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2778     Document Type: Article

References (50)

1. Cobaleda CSA, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol 2007;8:463-70.
2. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukemia. Nature 2007;446:758-64.
3. Busslinger M, Klix N, Pfeffer P, Graninger PG, Kozmik Z. Deregulation of PAX-5 by translocation of the Em enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. Proc Natl Acad Sci U S A 1996;93:6129-34.
4. Lida S, Rao PH, Nallasivam P, et al. The t(9;14) (p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood 1996;88:4110-7.
5. Cazzaniga G, Daniotti M, Tosi S, et al. The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. Cancer Res 2001;61:4666-70.
6. Strehl S, Konig M, Dworzak MN, Kalwak K, Haas OA. PAX5/ETV6 fusion defines cytogenetic entity dic(9;12) (p13;p13). Leukemia 2003;17:1121-3.
7. Nutt SL, Heavey B, Rolink A, Busslinger M. Commitment to the B-lymphoid lineage depends in the transcription factor Pax5. Nature 1999;401:556-62.
8. Morrison AM, Nutt S, Thevenin C, Rolink A, Busslinger M. Loss- and gain-of-function mutations reveal an important role of BSAP Pax-5 at the start and end of B cell differentiation. Immunology 1998;10:133-42.
9. Cotta CV, Zhang Z, Kim HG, Klug CA. Pax5 determines B- versus T-cell fate and does not block early myeloid-lineage development. Blood 2003;101:4342-6.
10. Souabni A, Cobaleda C, Schebesta M, Busslinger M. Pax5 promotes B lymphopoiesis and blocks T cell development by repressing Notch1. Immunity 2002;17:781-93.
11. Czerny T, Busslinger M. DNA-binding and transactivation properties of Pax-6: three amino acids in the paired domain are responsible for the different sequence recognition of Pax-6 and BSAP (Pax-5). Mol Cell Biol 1995;15:2858-71.
12. Ghia P, Bruno E, Rolink AG, Melchers F. B-cell development: a comparison between mouse and man. Immunol Today 1998;19.
13. Nutt SL, Morrison A, Dorfler P, Rolink A, Busslinger M. Indentification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. EMBO J 1998;17:2319-33.
14. Kozmik Z, Wang S, Dorfler P, Adams B, Busslinger M. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol Cell Biol 1992;12:2662-72.
15. Maier H, Ostraat R, Parenti S, et al. Requirements for selective recruitment of Ets proteins and activation of mb-1/Ig-a gene transcription by Pax-5 (BSAP). Nucleic Acids Res 2003;31:5483-9.
16. Schebesta M, Pfeffer PL, Busslinger M. Control of pre-BCR signaling by Pax5-dependent activation of the BLNK gene. Immunity 2002;17:473-85.
17. Holmes ML, Carotta S, Corcoran LM, Nutt SL. Repression of Flt3 by Pax5 is crucial for B-cell lineage commitment. Genes Dev 2006;20:933-8.
18. Horcher M, Souabni A, Busslinger M. Pax5/BSAP maintains the identity of B cells in late B lymphopoiesis. Immunity 2001;14:779-90.
19. Poirel H, Oury C, Carron C, et al. The TEL gene products: nuclear phosphoproteins with DNA binding properties. Oncogene 1997;14:349-57.
20. Lopez RG, Carron C, Oury C, Gardellin P, Bernard O, Ghysdael J. TEL is a sequence-specific transcriptional repressor. J Biol Chem 1999;274:30132-8.
21. Wang L, Hiebert SW. TEL contacts multiple corepressors and specifically associates with histone deacetylase-3. Oncogene 2001;20:3716-25.
22. Chakrabarti SR, Nucifora G. The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A. Biochem Biophys Res Commun 1999;264:871-7.
23. Guidez F, Petrie K, Ford AM, et al. Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. Blood 2000;96:2557-61.
24. Montpetit A, Sinnett D. Comparative analysis of the ETV6 gene in vertebrate genomes from pufferfish to human. Oncogene 2001;20:3437-42.
25. Wang LC, Kuo F, Fujiwara Y, Gilliland DG, Golub TR, Orkin SH. Yolk sac angiogenic defect and intraembryonic apoptosis in mice lacking the Ets-related factor TEL. EMBO J 1997;16:4374-83.
26. Wang LC, Swat W, Fujiwara Y, et al. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev 1998;12:2392-402.
27. Hock H, Meade E, Medeiros S, et al. Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. Genes Dev 2004;18:2336-41.
28. Poirel H, Lacronique V, Mauchauffe M, et al. Analysis of TEL proteins in human leukemias. Oncogene 1998;16:2895-903.
29. Bohlander SK. ETV6: a versatile player in leukemogenesis. Semin Cancer Biol 2005;15:162-74.
30. Rolink AG, Schaniel C, Melchers F. Stability and plasticity of wild-type and Pax5-deficient precursor B cells. Immunol Rev 2002;187:87-95.
31. Schaniel C, Gottar M, Roosnek E, Melchers F, Rolink AG. Extensive in vivo self-renewal, long-term reconstitution capacity, and hematopoietic multipotency of Pax5-deficient precursor B-cell clones. Blood 2002;99:2760-6.
32. Rolink AG, Schaniel C, Bruno L, Melchers F. In vitro and in vivo plasticity of Pax5-deficient pre-B I cells. Immunol Lett 2002;82:35-40.
33. Balciunaite G, Ceredig R, Massa S, Rolink AG. A B220+ CD117+ CD19- hematopoietic progenitor with potent lymphoid and myeloid developmental potential. Eur J Immunol 2005;35:2019-30.
34. Palmi C, Fazio G, Cassetti A, et al. TEL/ARG induces cytoskeletal abnormalities in 293T cells. Cancer Lett 2006;241:79-86.
35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 2001;25:402-8.
36. Szymczyna BR, Arrowsmith CH. DNA binding specificity studies of four ETS proteins support an indirect read-out mechanism of protein-DNA recognition. J Biol Chem 2000;275:28363-70.
37. -/- pre-B I cells. Cells Tissues Organs 2002;171:38-43.
38. D'Apuzzo M, Rolink A, Loetscher M, et al. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. Eur J Immunol 1997;27:1788-93.
39. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells. Blood 2006;107:1761-7.
40. Osmond DG, Rolink A, Melchers F. Murine B lymphopoiesis: towards a unified model. Immunol Today 1998;19:65-8.
41. Dong M, Blobe GC. Role of transforming growth factor-B in hematologic malignancies. Blood 2006;107:4589-96.
42. Bousquet M, Broccardo C, Quelen C, et al. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on the wild type PAX5. Blood 2007;109:3417-23.
43. Campana D, Coustan-Smith E, Manabe A, et al. Human B-cell progenitors and bone marrow microenvironment. Hum Cell 1996;9:317-22.
44. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 1995;18:385-97.
45. Melchers F, Haasner D, Streb M, Rolink A. Blymphocyte lineage-committed, IL-7 and stroma cell-reactive progenitors and precursors, and their differentiation to B cells. Adv Exp Med Biol 1992;323:111-7.
46. Van Zelm MC, van der Burg M, de Ridder D, et al. Ig gene rearrangement steps are initiated in early human precursor B cell subsets and correlate with specific transcription factor expression. J Immunol 2005;175:5912-22.
47. Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 1997;90:2863-92.
48. Mikkola I, Heavey B, Horcher M, Busslinger M. Reversion of B cell commitment upon loss of Pax5 expression. Science 2002;297:110-3.
49. Marin V, Dander E, Biagi E, et al. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in BALL immunotherapy. Exp Hematol 2006;34:1218-28.
50. Burger JA, Burkle A. The CXCR4 chemokine receptor in acute and chronic leukemia: a marrow homing receptor and potential therapeutic target. Br J Haematol 2007;137:288-96.